Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Engineering CAR-T therapies for autoimmune disease and beyond.
English EP, Swingler RN, Patwa S, Tosun M, Howard JF Jr, Miljković MD, Jewell CM. English EP, et al. Among authors: howard jf jr. Sci Transl Med. 2024 Oct 30;16(771):eado2084. doi: 10.1126/scitranslmed.ado2084. Epub 2024 Oct 30. Sci Transl Med. 2024. PMID: 39475572 Review.
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis.
de la Borderie G, Chimits D, Boroojerdi B, Brock M, Duda PW, Grimson F, Mahoney P, Strimenopoulou F, Cutter G, Aban I, Brauner S, Petersson M, Howard JF Jr, Bennett N. de la Borderie G, et al. Among authors: howard jf jr. Ther Adv Neurol Disord. 2024 Sep 21;17:17562864241279125. doi: 10.1177/17562864241279125. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 39314260 Free PMC article.
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
Howard JF Jr, Vu T, Li G, Korobko D, Smilowski M, Liu L, Gistelinck F, Steeland S, Noukens J, Van Hoorick B, Podhorna J, Borgions F, Li Y, Utsugisawa K, Wiendl H, De Bleecker JL, Mantegazza R; ADAPT-SC and ADAPT-SC+ Study Groups. Howard JF Jr, et al. Neurotherapeutics. 2024 Sep;21(5):e00378. doi: 10.1016/j.neurot.2024.e00378. Epub 2024 Sep 2. Neurotherapeutics. 2024. PMID: 39227284 Free article. Clinical Trial.
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF, Ginsberg M, Hoshino H, Mimaki M, Nagata S, Rao VK, Ruzhansky K, Suresh N, Tiongson E, Yamanouchi H, Frick G, Hicks E, Liao S, Howard JF Jr; MG 303 Study Group. Brandsema JF, et al. Among authors: howard jf jr. Pediatr Neurol. 2024 Jul;156:198-207. doi: 10.1016/j.pediatrneurol.2024.04.020. Epub 2024 Apr 26. Pediatr Neurol. 2024. PMID: 38810600 Free article. Clinical Trial.
CAR T-Cell Therapy in Autoimmune Disease.
Howard JF Jr, Vu T, Mozaffar T. Howard JF Jr, et al. N Engl J Med. 2024 May 2;390(17):1629-1631. doi: 10.1056/NEJMc2403705. N Engl J Med. 2024. PMID: 38692299 No abstract available.
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.
Howard JF Jr, Bresch S, Farmakidis C, Freimer M, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Nowak RJ, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Bloemers J, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Vanderkelen M, Leite MI; RAISE-XT Study Team*. Howard JF Jr, et al. Ther Adv Neurol Disord. 2024 Apr 17;17:17562864241243186. doi: 10.1177/17562864241243186. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38638673 Free PMC article.
139 results